1
|
Zheng C, Li J, Chen H, Ma X, Si T, Zhu W. Dual role of CD177 + neutrophils in inflammatory bowel disease: a review. J Transl Med 2024; 22:813. [PMID: 39223577 PMCID: PMC11370282 DOI: 10.1186/s12967-024-05539-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2024] [Accepted: 07/25/2024] [Indexed: 09/04/2024] Open
Abstract
Inflammatory bowel disease (IBD) represents a group of recurrent chronic inflammatory disorders associated with autoimmune dysregulation, typically characterized by neutrophil infiltration and mucosal inflammatory lesions. Neutrophils, as the earliest immune cells to arrive at inflamed tissues, play a dual role in the onset and progression of mucosal inflammation in IBD. Most of these cells specifically express CD177, a molecule increasingly recognized for its critical role in the pathogenesis of IBD. Under IBD-related inflammatory stimuli, CD177 is highly expressed on neutrophils and promotes their migration. CD177 + neutrophils activate bactericidal and barrier-protective functions at IBD mucosal inflammation sites and regulate the release of inflammatory mediators highly correlated with the severity of inflammation in IBD patients, thus playing a dual role. However, mitigating the detrimental effects of neutrophils in inflammatory bowel disease remains a challenge. Based on these data, we have summarized recent articles on the role of neutrophils in intestinal inflammation, with a particular emphasis on CD177, which mediates the recruitment, transepithelial migration, and activation of neutrophils, as well as their functional consequences. A better understanding of CD177 + neutrophils may contribute to the development of novel therapeutic targets to selectively modulate the protective role of this class of cells in IBD.
Collapse
Affiliation(s)
- Chengli Zheng
- Department of Hematology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China
| | - Jiekai Li
- Department of Hematology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China
| | - Hailin Chen
- Department of Hematology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China
| | - Xiaolin Ma
- Department of Hematology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China
| | - Tianyu Si
- Department of Hematology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China
| | - Wenwei Zhu
- Department of Hematology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
| |
Collapse
|
2
|
Traum A, Jehle S, Waxmann Y, Litmeyer AS, Berghöfer H, Bein G, Dammann R, Perniss A, Burg-Roderfeld M, Sachs UJ, Bayat B. The CD177 c.1291A Allele Leads to a Loss of Membrane Expression and Mimics a CD177-Null Phenotype. Int J Mol Sci 2024; 25:2877. [PMID: 38474126 DOI: 10.3390/ijms25052877] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2023] [Revised: 02/18/2024] [Accepted: 02/20/2024] [Indexed: 03/14/2024] Open
Abstract
CD177 is a glycosyl phosphatidyl inositol (GPI)-linked, neutrophil-specific glycoprotein that in 3-5% of normal individuals is absent from all neutrophils. The molecular mechanism behind the absence of CD177 has not been unravelled completely. Here, we analyse the impact of the recently described CD177 c.1291G>A variant on CD177 expression. Recombinant CD177 c.1291G>A was expressed in HEK293F cells and its expression on the cell surface, inside the cell, and in the culture supernatant was investigated. The CD177 c.1291G>A protein was characterised serologically and its interaction with proteinase 3 (PR3) was demonstrated by confocal laser scanning microscopy. Our experiments show that CD177 c.1291G>A does not interfere with CD177 protein biosynthesis but affects the membrane expression of CD177, leading to very low copy numbers of the protein on the cellular surface. The mutation does not interfere with the ability of the protein to bind PR3 or human polyclonal antibodies against wild-type CD177. Carriers of the c.1291G>A allele are supposed to be phenotyped as CD177-negative, but the protein is present in soluble form. The presence of CD177 c.1291A leads to the production of an unstable CD177 protein and an apparent "CD177-null" phenotype.
Collapse
Affiliation(s)
- Annalena Traum
- Institute for Clinical Immunology, Transfusion Medicine and Haemostasis, Medical Faculty, Justus-Liebig-University, 35390 Giessen, Germany
| | - Stefanie Jehle
- Institute for Clinical Immunology, Transfusion Medicine and Haemostasis, Medical Faculty, Justus-Liebig-University, 35390 Giessen, Germany
| | - Yannick Waxmann
- Institute for Clinical Immunology, Transfusion Medicine and Haemostasis, Medical Faculty, Justus-Liebig-University, 35390 Giessen, Germany
| | - Anne-Sophie Litmeyer
- Institute for Clinical Immunology, Transfusion Medicine and Haemostasis, Medical Faculty, Justus-Liebig-University, 35390 Giessen, Germany
| | - Heike Berghöfer
- Institute for Clinical Immunology, Transfusion Medicine and Haemostasis, Medical Faculty, Justus-Liebig-University, 35390 Giessen, Germany
| | - Gregor Bein
- Institute for Clinical Immunology, Transfusion Medicine and Haemostasis, Medical Faculty, Justus-Liebig-University, 35390 Giessen, Germany
| | - Reinhard Dammann
- Institute for Genetics, Faculty of Biology and Chemistry, Justus-Liebig-University, 35390 Giessen, Germany
| | - Alexander Perniss
- Institute for Anatomy and Cell Biology, German Center for Lung Research, Excellence Cluster Cardio-Pulmonary Institute (CPI), Justus-Liebig-University, 35392 Giessen, Germany
| | - Monika Burg-Roderfeld
- Faculty of Biology and Chemistry, Fresenius University of Applied Sciences, 65510 Idstein, Germany
| | - Ulrich J Sachs
- Institute for Clinical Immunology, Transfusion Medicine and Haemostasis, Medical Faculty, Justus-Liebig-University, 35390 Giessen, Germany
- Department of Thrombosis and Haemostasis, Giessen University Hospital, 35390 Giessen, Germany
| | - Behnaz Bayat
- Institute for Clinical Immunology, Transfusion Medicine and Haemostasis, Medical Faculty, Justus-Liebig-University, 35390 Giessen, Germany
| |
Collapse
|
3
|
Ishimoto Y, Taniguchi K, Bayat B, Tobita R, Miyazaki T, Onodera R, Kurita E, Kobayashi M, Muroi K, Tsuno NH. Production of recombinant humanized monoclonal anti-human neutrophil antigen (HNA) antibodies with potential applicability as standard antibodies. Transfusion 2023; 63:2282-2288. [PMID: 37952222 DOI: 10.1111/trf.17590] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2023] [Revised: 10/07/2023] [Accepted: 10/07/2023] [Indexed: 11/14/2023]
Abstract
BACKGROUND Antibodies against human neutrophil antigen (HNA) are involved in the pathogenesis of neonatal alloimmune neutropenia, autoimmune neutropenia, and transfusion-related acute lung injury. The present methods for anti-HNA antibody identification strongly depend on the presence of standard antisera with known allo/isospecificities. Here, we aimed to produce recombinant humanized antibodies to HNA from available mouse monoclonal antibodies (MoAbs). STUDY DESIGN AND METHODS RNAs were extracted from available hybridoma cells producing mouse anti-HNA antibodies recognizing HNA-1a (TAG-1), -1b (TAG-2), -2 (TAG-4), and FcγRIIIb, and the cDNA was synthesized. Recombinant fragments consisting of the variable regions of the H and L chains of the mouse MoAb ligated to the constant region of human IgG were incorporated into an expression vector and transfected into CHO cells. Antibody specificity of the selected humanized monoclonal antibodies was confirmed, and tested by the participants of the ISBT Granulocyte Immunobiology Working Party (GIWP) workshop 2020. RESULTS GIFT results confirmed the specific reactivity of TAGH-1 to -4, except for a cross-reactivity of TAGH-2 with HNA-1a/a neutrophils, only in flow-cytometry. MAIGA results showed clear specificity of all humanized antibodies, but the selection of the appropriate capture monoclonal antibody was essential for the test. The results of the ISBT GIWP showed high concordance among the labs. CONCLUSIONS These are the first humanized monoclonal antibodies to HNA-1 and HNA-2 antigens produced and they will be important standard reagents for laboratories testing for neutrophil antibodies. We plan to have these humanized MoAbs available through WHO.
Collapse
Affiliation(s)
- Yuko Ishimoto
- Kanto-Koshinetsu Block Blood Center, Japanese Red Cross Society, Tokyo, Japan
| | - Kikuyo Taniguchi
- Department of Clinical Laboratory Science, Sanyo Women's College, Hiroshima, Japan
| | - Behnaz Bayat
- Institute for Clinical Immunology and Transfusion Medicine, Justus Liebig University Giessen, Giessen, Germany
| | - Ryutaro Tobita
- Kanto-Koshinetsu Block Blood Center, Japanese Red Cross Society, Tokyo, Japan
| | - Toru Miyazaki
- Research and Development Department, Japanese Red Cross Central Blood Institute, Tokyo, Japan
| | - Rie Onodera
- Department of Clinical Laboratory Science, Sanyo Women's College, Hiroshima, Japan
| | - Emi Kurita
- Division of Transfusion Medicine, Hiroshima University, Hiroshima, Japan
| | - Masao Kobayashi
- Japanese Red Cross Society Chushikoku Block Blood Center, Hiroshima, Japan
| | - Kazuo Muroi
- Kanto-Koshinetsu Block Blood Center, Japanese Red Cross Society, Tokyo, Japan
| | | |
Collapse
|
4
|
Li Y, Schuller RM, Wu J. An accurate genetic assay to identify human neutrophil antigen 2 deficiency. Transfus Med 2023; 33:68-74. [PMID: 36308061 PMCID: PMC9974537 DOI: 10.1111/tme.12936] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2022] [Revised: 09/08/2022] [Accepted: 10/15/2022] [Indexed: 10/31/2022]
Abstract
OBJECTIVE We aimed to develop accurate and user-friendly genetic assays to identify the inherited neutrophil antigen-2 (HNA-2) deficiency in humans. BACKGROUND HNA-2 is one of the most important neutrophil antigens implicated in a number of human disorders. HNA-2 deficiency or HNA-2 null is a common phenotype observed in 3%-5% Americans. HNA-2 null individuals are at risk to produce isoantibodies (or alloantibodies) that play important roles in transfusion-related acute lung injury, immune neutropenia, and bone marrow graft failure. We previously demonstrated that the CD177 coding SNP 787A > T (c.787A > T) is the most important genetic determinant for HNA-2 deficiency. However, reliable genetic assays are not available for routine clinical laboratory application up to now. STUDY DESIGN AND METHODS A novel polymerase chain reaction (PCR) strategy was used to determine genotypes of the CD177 SNP c.787A > T. In the simplified PCR assay, all allele specific primers and internal control primers were included in the same reaction, which ensures reliability of the assay. In addition, a novel high-throughput nested TaqMan assay was developed to determine genotypes of c.787A > T for large population genetic analysis of HNA-2 deficiency. RESULTS CD177 SNP c787A > T genotypes of 396 subjects were 100% concordant among the single PCR reaction method, the nested TaqMan assay, and Sanger Sequencing analysis. Out of 396 subjects, all 18 donors with the CD177 STP homozygous genotype were HNA-2 null. CONCLUSION The novel PCR-based genotyping assay is accurate to identify HNA-2 deficient individuals and is suitable for clinical laboratories. In addition, the innovative high-throughput nested TaqMan assay will be useful for large-scale population screens and genetic studies of HNA-2 deficiency.
Collapse
Affiliation(s)
- Yunfang Li
- Department of Veterinary and Biomedical Sciences, University of Minnesota. St. Paul, MN
| | - Randy M. Schuller
- American Red Cross, North Central Blood Services, National Neutrophil Reference Laboratory, St. Paul, MN
| | - Jianming Wu
- Department of Veterinary and Biomedical Sciences, University of Minnesota. St. Paul, MN
| |
Collapse
|
5
|
Bergman P, Broliden P, Ratcliffe P, Lourda M, Flesch B, Höglund P, Palmblad J. Mutation in the TACI gene and autoimmune neutropenia: A case report. Am J Hematol 2022; 97:E207-E210. [PMID: 35293001 DOI: 10.1002/ajh.26532] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2021] [Revised: 03/01/2022] [Accepted: 03/11/2022] [Indexed: 01/02/2023]
Affiliation(s)
- Peter Bergman
- Department of Infectious Diseases Karolinska University Hospital Huddinge Stockholm Sweden
- Laboratory Medicine, Karolinska Institutet Stockholm Sweden
| | - Per‐Anders Broliden
- Department of Hematology Karolinska University Hospital Huddinge Stockholm Sweden
| | - Paul Ratcliffe
- Department of Clinical Immunology Transfusion Medicine, Karolinska University Hospital Huddinge Stockholm Sweden
- Center for Hematology and Regenerative Medicine (HERM), Department of Medicine Huddinge Karolinska Institutet Stockholm Sweden
| | - Magda Lourda
- Center for Infectious Medicine, Department of Medicine Huddinge Karolinska Institutet Stockholm Sweden
- Childhood Cancer Research Unit, Department of Women's and Children's Health Karolinska Institutet Stockholm Sweden
| | - Brigitte Flesch
- German Red Cross Blood Service Rhineland‐Palatinate and Saarland Bad Kreuznach Germany
- German Red Cross Blood Service West Hagen Germany
| | - Petter Höglund
- Department of Clinical Immunology Transfusion Medicine, Karolinska University Hospital Huddinge Stockholm Sweden
- Center for Hematology and Regenerative Medicine (HERM), Department of Medicine Huddinge Karolinska Institutet Stockholm Sweden
| | - Jan Palmblad
- Department of Hematology Karolinska University Hospital Huddinge Stockholm Sweden
| |
Collapse
|
6
|
Browne T, Wroe E, Keen L, Poles A. Human neutrophil antigen 2 sequence-based typing: Joining the hunt for the CD177 answer. Vox Sang 2021; 117:431-437. [PMID: 34590317 DOI: 10.1111/vox.13209] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2021] [Revised: 09/07/2021] [Accepted: 09/13/2021] [Indexed: 12/23/2022]
Abstract
BACKGROUND AND OBJECTIVES Isoantibodies to human neutrophil antigen 2 (CD177) have been associated with several clinical conditions but to date the molecular basis for altered or non-expression has not been determined. Reliance on phenotyping and crossmatch to investigate these neutropenic clinical cases are inconvenient for the patients and demanding of resources within the laboratory. Therefore, a molecular approach has been introduced to address both issues. MATERIALS AND METHODS A DNA panel of 100 randomly selected blood donors were collected and supplemented with 18 DNA samples from blood donors previously shown to be CD177 null. All DNA samples were sequence-based typed for all exons and observed polymorphisms recorded. The DNA from two families previously investigated for neonatal alloimmune neutropenia due to CD177 isoantibodies were also analysed. RESULTS The incidence of CD177 null could be associated with a known exon 7 single-nucleotide polymorphism in 16/21 known CD177 null samples, which is consistent with previously published findings. Two additional mutations that may lead to null expression were also identified, of which one may be novel. In both family investigations, this same mutation could also be observed in the maternal DNA sample. CONCLUSION Based on these observations, introduction of CD177 genotyping into routine use would identify null expression in over 75% (16/21) of associated cases. In turn, this could significantly reduce the need for supplementary testing and associated inconvenience to patients while permitting increased efficiency of laboratory testing. An added benefit would potentially elucidate other clinically relevant mutations and associated antigenic targets.
Collapse
Affiliation(s)
- Tom Browne
- Histocompatibility and Immunogenetics Laboratory, NHS Blood and Transplant, Bristol, UK
| | - Elizabeth Wroe
- Histocompatibility and Immunogenetics Laboratory, NHS Blood and Transplant, Bristol, UK
| | - Leigh Keen
- Histocompatibility and Immunogenetics Laboratory, NHS Blood and Transplant, Bristol, UK
| | - Anthony Poles
- Histocompatibility and Immunogenetics Laboratory, NHS Blood and Transplant, Bristol, UK
| |
Collapse
|